Calidi Biotherapeutics to Showcase RedTail Platform Data at ASGCT Conference
Event summary
- Calidi Biotherapeutics' CSO Antonio F. Santidrian to present at ASGCT conference on May 14, 2026.
- New data on CLD-401, a systemically delivered virotherapy targeting tumors with IL-15 superagonist.
- Company expects to file IND for CLD-401 by the end of 2026.
- RedTail platform also enables in situ expression of tumor-targeted T cell engagers (CLD-501).
The big picture
Calidi's presentation at ASGCT underscores the growing interest in systemic virotherapies for metastatic cancers. The RedTail platform's ability to deliver genetic medicines to distal tumor sites positions it within the competitive landscape of next-generation oncology treatments. Success in translating preclinical data into clinical outcomes will be critical for Calidi's valuation and market positioning.
What we're watching
- Clinical Timelines
- Whether Calidi can meet its IND filing target for CLD-401 by year-end 2026.
- Platform Expansion
- The pace at which RedTail can demonstrate efficacy across multiple tumor types.
- Partnership Strategy
- How strategic collaborations will accelerate RedTail's clinical development.
Related topics